Balanced
Affordable cancer care needs more than price caps
The government capped trade margins on non-scheduled cancer drugs at 30% to address unaffordable costs from high intermediary mark-ups. Yet, the intervention's effectiveness is limited; it doesn't address manufacturer prices, especially for patented drugs, potentially keeping treatment costly. Prior caps yielded mixed results, and artificial discounts distort the market. The author urges stricter scrutiny of manufacturers' prices and transparent sales reporting. Comprehensive price control requires integrating with stronger public health services, wider insurance coverage, and more generics research for affordability.
Indian Express · Editorial · Oct 30, 2026 at 12:35 AM